Viatris vs Idexx Laboratories
Side-by-side comparison of AI visibility scores, market position, and capabilities
Viatris (VTRS) reported ~$15.4B revenue in FY2024. Global generic and specialty pharmaceutical company formed by Pfizer's Upjohn spinoff merging with Mylan. HQ: Canonsburg, PA.
About
Viatris Inc. is a global pharmaceutical company formed in 2020 through the combination of Pfizer's off-patent branded drug unit (Upjohn) and Mylan, one of the world's largest generic drug manufacturers. The company manufactures, licenses, and distributes approximately 1,400 approved molecules across branded generics, complex generics, and a portfolio of iconic off-patent brands including Lipitor (atorvastatin), Viagra (sildenafil), EpiPen, and Xanax (alprazolam) sold in markets where these brands retain meaningful recognition and premium pricing.
Veterinary diagnostics leader with $3.81B FY2024 revenue; 130,000+ analyzer installed base; AI-powered inVue Dx digital cytology; VetConnect data platform; pet humanization tailwind.
About
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headquartered. The company trades on Nasdaq (IDXX) and reported $3.81 billion in revenues for FY2024, maintaining its dominant position in point-of-care veterinary diagnostics through an installed base of over 130,000 Catalyst chemistry analyzers, ProCyte hematology systems, and SNAP rapid assay devices deployed in veterinary clinics worldwide. CEO Jay Mazelsky has continued IDEXX's expansion into AI-powered diagnostics and digital pathology, building on over four decades of veterinary-specific product development.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.